HK Stock Market Move | Huaren Bio-B (02396) fell more than 12% in the morning session, hitting a new low, halving its IPO price.

Huaren Bio-B (02396) fell by more than 12%, hitting a new low of 18.6 Hong Kong dollars, which is half of the IPO price of 38.2 Hong Kong dollars. As of the time of writing, it dropped by 11.77% to 18.67 Hong Kong dollars, with a turnover of 7.462 million Hong Kong dollars. It is reported that Huaren Bio is a biopharmaceutical company focusing on the discovery, development, and commercialization of wound healing therapies. As of December 5, 2025, the company's pipeline includes ten candidate products, with seven of them being PDGF candidate drugs, including the core products Pro-101-1 and Pro-101-2. Financially, the company has not generated any revenue through product sales. The company's net losses for 2023, 2024, and up to September 30, 2025, were 110 million yuan, 210 million yuan, and 130 million yuan, respectively. The vast majority of the company's net losses come from research and development expenses and administrative expenses.